Navigation Links
Immucor Announces Fiscal Year 2009 Revenue and Earnings Guidance
Date:6/4/2008

NORCROSS, Ga., June 4 /PRNewswire-FirstCall/ -- Immucor, Inc. (Nasdaq: BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced revenue and earnings guidance for the fiscal year ending May 31, 2009.

For fiscal year 2009:

-- The company expects revenues to range from $292 million to

$300 million.

-- Gross margin is expected to be in the range of 70% to 71%.

-- Net income is expected to be in the range of $80.0 million to

$83.0 million.

-- We expect to generate earnings per diluted share in the range of

$1.11 to $1.15.

We base our projections on our history of operations, the recurring nature of a significant portion of our revenues, including contractually committed purchases from large customers, and the predictability of our expenses through the fiscal year.

In making this projection, management has made the following assumptions:

-- With respect to revenues, the Company has extrapolated recent past

results and assumed the Company will generate additional revenues from

the implementation of our price strategy, the continuing sales of the

Galileo(R) and Echo(R) instruments in North America, Japan and Europe

and the reagent growth associated with these instrument placements.

-- With respect to the pending BioArray acquisition, the Company has

excluded the impact of the acquisition from these projections. As

previously announced the Company expects dilution of approximately

$0.20 to $0.23 in EPS in the first full year of operations following

closing, including approximately $0.05 per share of dilution resulting

from non-cash amortization expense.

-- With respect to stock based compensation expense, the Company expects

an increase of approximately $1.0 million.

Immucor, Inc. will host a confe
'/>"/>

SOURCE Immucor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Immucor CEOs Italian Trial Moves Toward Second Phase
2. Immucor To Acquire BioArray Solutions Ltd.
3. Immucor Responding to FTC Inquiry
4. Immucor Settles SEC Investigation
5. Martek Announces Second Quarter 2008 Financial Results
6. WWMR, Inc. Announces Launch of New Pain Clinic Monitor
7. China Kangtai Cactus Biotech Announces Improved Milk Production in Cows From Companys Cactus Cattle Feed
8. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
9. Exelixis Announces June 10 Webcast of Presentation at the Goldman Sachs 29th Annual Global Healthcare Conference
10. Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment
11. Cynosure Announces Schedule of Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... PA (PRWEB) October 17, 2014 ... being called upon by health facilities around the ... patients are being treated. Among the many places ... includes Texas Health Presbyterian Hospital Dallas and at ... The state-of-the-art vapor-producing robots have been utilized to ...
(Date:10/17/2014)... The global SWIR market report defines and ... of revenue. This market is valued at $60.1 million ... by 2019, at a CAGR of 10.2% from 2014 ... global SWIR market report, to get an idea of ... of the segmentation of the market, and is supported ...
(Date:10/17/2014)... The North American Knowledge-based/Evidence-based Clinical ... segments the market in North America with analysis ... in North America is expected to reach around ... of 8.1% from 2013 to 2018. , Browse ... clinical decision support system (CDSS) market, to get ...
(Date:10/17/2014)... The Middle East and Africa Location Based Services (LBS) ... Middle East and Africa with analysis and forecast of revenue. ... 2014 to $3,403.1 million by 2019, at a CAGR of ... of the Middle East and Africa Location Based Services (LBS) ... provided. It also provides a glimpse of the market segmentation, ...
Breaking Biology Technology:Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 2Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 3Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 4Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 5Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 6The global SWIR market is expected to reach $97.9 million by 2019 - New Report by MicroMarket Monitor 2The global SWIR market is expected to reach $97.9 million by 2019 - New Report by MicroMarket Monitor 3The North American Knowledge-based/Evidence-based Clinical Decision Support System (CDSS) market is expected to reach around $283.3 million by 2018 - MicroMarket Monitor 2The North American Knowledge-based/Evidence-based Clinical Decision Support System (CDSS) market is expected to reach around $283.3 million by 2018 - MicroMarket Monitor 3The North American Knowledge-based/Evidence-based Clinical Decision Support System (CDSS) market is expected to reach around $283.3 million by 2018 - MicroMarket Monitor 4The North American Knowledge-based/Evidence-based Clinical Decision Support System (CDSS) market is expected to reach around $283.3 million by 2018 - MicroMarket Monitor 5The Middle East and Africa Location Based Services (LBS) market is estimated to reach $3,403.1 million by 2019 - New Report by MicroMarket Monitor 2The Middle East and Africa Location Based Services (LBS) market is estimated to reach $3,403.1 million by 2019 - New Report by MicroMarket Monitor 3The Middle East and Africa Location Based Services (LBS) market is estimated to reach $3,403.1 million by 2019 - New Report by MicroMarket Monitor 4
... CITY, Dec. 4 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... company focused on endocrine therapy and oncology, today announced ... take part in a panel discussion titled, "Replacing The ... RBC Capital Markets 2008 Healthcare Conference on Wednesday, December ...
... and secondhand smoke, an estimated ten percent of pregnant women ... baby to harmful cigarette byproducts from mothers who smoke affects ... health care burden. , Now, in the first study of ... assessment of newborns, umbilical cord blood to better understand the ...
... Dec. 3 CeloNova BioSciences, Inc., announced,today that ... is commercializing the,CATANIA(TM) Coronary Stent System with NanoThin ... any stent thrombosis in clinical studies. It is ... now some Middle,Eastern countries with aggressive world-wide expansion ...
Cached Biology Technology:Cutting the cord to determine babies' health risk from toxic exposure 2Cutting the cord to determine babies' health risk from toxic exposure 3Cutting the cord to determine babies' health risk from toxic exposure 4CeloNova BioSciences Commercializes CATANIA(TM) Coronary Stent With NanoThin Polyzene(R)-F in Europe and Middle East 2CeloNova BioSciences Commercializes CATANIA(TM) Coronary Stent With NanoThin Polyzene(R)-F in Europe and Middle East 3
(Date:10/17/2014)... Ebola is critical and pertinent for practicing physicians and ... and epidemic. The Journal, Disaster Medicine and Public ... Virus and Public Health, to surround the public, medical ... societal moment. , On October 17, the journal ... The primer was prepared by Dr. Eric Toner, internist ...
(Date:10/16/2014)... war on the human body. Battles are won, ... pancreatic cancer, this stalemate—known as tumor dormancy—can last ... a phenomena that is poorly understood. , ... of Salvatore Torquato, a Professor of Chemistry at ... tumor dormancy and the switch to a malignant ...
(Date:10/16/2014)... they are anything but sustainable: environmental damage to ... becoming increasingly evident. Despite their disadvantages, however, monocultures ... as the sole possibility of achieving higher yields ... Schmid, an ecology professor at the University of ... and forestry. After all, a new study carried ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3
... that the amount of health-linked polyphenols present during roasting ... and might be used to limit the generation of ... family of naturally occurring plant components that have been ... Flavonoids and some anti-oxidants belong to the polyphenol family ...
... has shown promise in skin disease and hemophilia might one ... new study by researchers at Stanford University School of Medicine. ... the Proceedings of the National Academy of Sciences the week ... a healthy copy of the gene dystrophin into mice with ...
... and Infectious Diseases (NIAID), part of the National ... drug candidate attacks the bacterium that causes tuberculosis ... the National Academy of Sciences, the finding may ... targets Mycobacterium tuberculosis (M. tb). , "PA-824, ...
Cached Biology News:Chemical compound inhibits tumor growth, size in new mouse study 2Chemical compound inhibits tumor growth, size in new mouse study 3Gene therapy for muscular dystrophy fixes frail muscle cells in animal model, Stanford study finds 2Gene therapy for muscular dystrophy fixes frail muscle cells in animal model, Stanford study finds 3NIAID researchers show how promising TB drug works 2NIAID researchers show how promising TB drug works 3
Capture faint-light images without losing sensitivity or resolution. With its brand new hardware and interface design, the LAS-1000plus turns sample imaging into a simple process....
This pump accomodates StemSep ; pump feed columns of the following sizes : 0.3in., 0.5in., 0.6in., and 1.0in.....
Designed for use with the Agencourt CleanSEQ and Agencourt AMPure 384-well SPRI reagent kits. For use with 384-well thermal cycling plates....
...
Biology Products: